These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 36106755)

  • 41. Microarchitecture of medication-related osteonecrosis of the jaw (MRONJ); a retrospective micro-CT and morphometric analysis.
    Schoenhof R; Munz A; Yuan A; ElAyouti A; Boesmueller H; Blumenstock G; Reinert S; Hoefert S
    J Craniomaxillofac Surg; 2021 Jun; 49(6):508-517. PubMed ID: 33707134
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnosis and Staging of Medication-Related Osteonecrosis of the Jaw.
    Ruggiero SL
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):479-87. PubMed ID: 26293329
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A nested case-control study of factors contributing to the development of medication-related osteonecrosis of the jaw in patients using bone resorption inhibitors in Mishima City.
    Seki K; Kamimoto A; Wada M; Iinuma T
    J Oral Sci; 2023 Jul; 65(3):184-189. PubMed ID: 37245962
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In Vitro Cytotoxicity of Antiresorptive and Antiangiogenic Compounds on Oral Tissues Contributing to MRONJ: Systematic Review.
    Guirguis RH; Tan LP; Hicks RM; Hasan A; Duong TD; Hu X; Hng JYS; Hadi MH; Owuama HC; Matthyssen T; McCullough M; Canfora F; Paolini R; Celentano A
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371553
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Navigating the complexities and controversies of medication-related osteonecrosis of the jaw (MRONJ): a critical update and consensus statement.
    Coropciuc R; Moreno-Rabié C; De Vos W; Van de Casteele E; Marks L; Lenaerts V; Coppejans E; Lenssen O; Coopman R; Walschap J; Nadjmi N; Jacobs R; Politis C; Van den Wyngaert T
    Acta Chir Belg; 2024 Feb; 124(1):1-11. PubMed ID: 38059301
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Medication-Related Osteonecrosis of the Jaw in Cancer Patients: Result from the OneFlorida Clinical Research Consortium.
    Yang G; Williams R; Wang L; Farhadfar N; Chen Y; Loiacono AT; Bian J; Holliday LS; Katz J; Gong Y
    J Bone Miner Res; 2022 Dec; 37(12):2466-2471. PubMed ID: 36151778
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: conservative treatment is effective up to stage 2.
    Coropciuc RG; Grisar K; Aerden T; Schol M; Schoenaers J; Politis C
    Br J Oral Maxillofac Surg; 2017 Oct; 55(8):787-792. PubMed ID: 28760314
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
    Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):871-877. PubMed ID: 33791853
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab.
    Matsumoto A; Sasaki M; Schmelzeisen R; Oyama Y; Mori Y; Voss PJ
    Clin Oral Investig; 2017 Jan; 21(1):127-134. PubMed ID: 26924135
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention.
    Di Fede O; Panzarella V; Mauceri R; Fusco V; Bedogni A; Lo Muzio L; Sipmo Onj Board ; Campisi G
    Biomed Res Int; 2018; 2018():2684924. PubMed ID: 30306086
    [TBL] [Abstract][Full Text] [Related]  

  • 52. How we manage medication-related osteonecrosis of the jaw.
    Byrne H; O'Reilly S; Weadick CS; Brady P; Ríordáin RN
    Eur J Med Res; 2024 Aug; 29(1):402. PubMed ID: 39095845
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Medication-related osteonecrosis of the jaw: Surgical or non-surgical treatment?
    Favia G; Tempesta A; Limongelli L; Crincoli V; Maiorano E
    Oral Dis; 2018 Mar; 24(1-2):238-242. PubMed ID: 29480596
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).
    Aguirre JI; Castillo EJ; Kimmel DB
    Bone; 2021 Dec; 153():116184. PubMed ID: 34520898
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Dentist's Perspective on the Need for Interdisciplinary Collaboration to Reduce Medication-Related Osteonecrosis of the Jaw.
    Griffin A; Brain P; Hancock C; Jeyapalina S
    Sr Care Pharm; 2022 Sep; 37(9):458-467. PubMed ID: 36038998
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antimicrobial peptide gene expression in medication-related osteonecrosis of the jaw.
    Thiel Y; Ghayor C; Lindhorst D; Essig H; Weber F; Rücker M; Schumann P
    Pathol Res Pract; 2020 Dec; 216(12):153245. PubMed ID: 33065485
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-angiogenic drug aggravates the degree of anti-resorptive drug-based medication-related osteonecrosis of the jaw by impairing the proliferation and migration function of gingival fibroblasts.
    Zhao N; Li QX; Wang YF; Qiao Q; Huang HY; Guo CB; Guo YX
    BMC Oral Health; 2023 May; 23(1):330. PubMed ID: 37245004
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.
    Hasegawa T; Hayashida S; Kondo E; Takeda Y; Miyamoto H; Kawaoka Y; Ueda N; Iwata E; Nakahara H; Kobayashi M; Soutome S; Yamada SI; Tojyo I; Kojima Y; Umeda M; Fujita S; Kurita H; Shibuya Y; Kirita T; Komori T;
    Osteoporos Int; 2019 Jan; 30(1):231-239. PubMed ID: 30406309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review.
    Aljohani S; Fliefel R; Ihbe J; Kühnisch J; Ehrenfeld M; Otto S
    J Craniomaxillofac Surg; 2017 Sep; 45(9):1493-1502. PubMed ID: 28687467
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Medication-related Osteonecrosis of the Jaw Induced by Regenerative Therapy in Implant Dentistry: A Scoping Review.
    Al-Omari FA; Kuroshima S; Sawase T
    J Dent; 2023 Nov; 138():104682. PubMed ID: 37708930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.